新西兰药房将为经事先治疗后符合资格的肾癌病人提供 " Opdivo " 基金。 New Zealand's Pharmac will fund Opdivo® for eligible kidney cancer patients after prior therapy.

新西兰药房将资助Opdivoí (nivolumab)治疗符合资格的病人,这些病人以前曾接受过抗血管诱变性治疗,但患有经转移的细胞肾脏癌。 New Zealand's Pharmac will fund Opdivo® (nivolumab) for eligible patients with metastatic clear cell renal cell carcinoma who have previously received anti-angiogenic therapy. 这一决定是在2024年6月政府增加资金之后作出的。 This decision follows a government funding increase in June 2024. 欧普迪沃是首个批准用于这种类型癌的免疫疗法,这是新西兰第八个最常见的癌症,在2022年报告了671例新病例. Opdivo is the first immunotherapy approved for this type of kidney cancer, which is the eighth most common cancer in New Zealand, with 671 new cases reported in 2022.

November 02, 2024

3 文章